Protagonist Therapeutics, Inc.
PTGX
$96.75
$4.394.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.82% | -13.14% | -198.34% | -108.85% | 496.49% |
| Total Depreciation and Amortization | -285.65% | -46.44% | 7.92% | 50.75% | -17.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.29% | -1.38% | -21.88% | 81.87% | -13.57% |
| Change in Net Operating Assets | -109.50% | 823.41% | -103.11% | 174.34% | -6,284.51% |
| Cash from Operations | -1,808.88% | 93.27% | -122.96% | 529.65% | -4.72% |
| Capital Expenditure | -63.64% | 89.18% | -49.17% | -75.81% | 60.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 183.74% | -205.11% | 159.26% | -1,015.35% | 95.95% |
| Cash from Investing | 183.37% | -206.83% | 158.06% | -981.97% | 95.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -49.87% | 93.47% | -75.47% | 195.76% | -66.55% |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -49.87% | 93.47% | -74.44% | 183.87% | -66.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 126.77% | -289.37% | -31.72% | 225.19% | 84.91% |